Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02364206
Other study ID # 2013-005442-11
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date June 8, 2015
Est. completion date August 2019

Study information

Verified date August 2019
Source Centre Jean Perrin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Glioblastomas are extremely resistant to treatment, including radiotherapy and/or chemotherapy. Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation. Activation of p38 MAPK has been associated with a poor prognosis among patients with glioblastoma during the temozolomide (TMZ) era and represents a compensatory response by tumor cell to environmental stress such as radiation or chemotherapy.

LY2228820 is a potent and selective inhibitor of p38 MAPK, and reduces phosphorylation of its cellular target, MAPK-activated protein kinase 2 (MAPKAPK-2) . LY2228820 is a good candidate to target malignant glioma resistance to the gold standard treatment combining radiation and TMZ by acting on both tumor and stromal cells.

The primary objectives of this study were to determine the recommended dose of LY2228820 in combination with TMZ and radiotherapy during chemoradiotherapy period (phase I) and to estimate the 6-month progression free survival (PFS) rate of patients treated with LY2228820 when administered at the recommended dose in combination with radiotherapy and concomitant TMZ (phase II)


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date August 2019
Est. primary completion date August 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Newly diagnosed and histologically confirmed glioblastoma

- Recursive partitioning analysis (RPA) class III or IV

- Age > or = 18 years and < 75 years of age

- Life expectancy > or = 6 months

- Patient must have at least 1 formalin fixed paraffin embedded tumor tissue block representative of glioblastoma available for pathology central review and biomarker exploration

- Adequate hematologic (absolute neutrophil count (ANC) > or = 1.5 x 109/L, platelet count > or = 100 x 109/L, hemoglobin > or = 10 g/dL ), renal (creatinine > or = 1.25 x ULN ), and hepatic function (total bilirubin < or = 1.5 x ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < or = 2.5 x ULN)

- Patients who were receiving corticosteroids had to receive a stable or decreasing dose for at least 14 days before enrollment

- Patients must be able to swallow and retain oral medication

- Women must have a negative serum pregnancy test less than 7 days prior to the first dose of study drug

- Both men and women of reproductive potential agree to use approved contraception during the study and for 6 months after discontinuation of study treatment.

- Willing and able to comply with the protocol as judged by the investigator

- Patients must provide written consent

Exclusion Criteria:

- Any prior chemotherapy (including carmustine-containing wafers) or immunotherapy (including vaccine therapy )

- Any prior radiotherapy to the brain

- Any contraindication to temozolomide listed in the local label

- Have had, in the judgment of the investigator, a major bowel resection that would alter oral drug absorption

- Have a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis)

- Have previously completed or withdrawn from this study or any other study investigating LY2228820

- Are receiving, in the judgment of the investigator, concurrent administration of immunosuppressive therapy

- Diarrhea of any cause CTCAE > or = grade 2

- Current or recent (within 30 days of enrollment) treatment with another investigational drug or participation in another investigational study

- History of other malignancy within 5 years prior enrollment except for basal cell carcinoma of the skin or carcinoma in situ of the cervix

- Pregnant or nursing (lactating) woman, or fertile women unwilling or unable to use effective means of contraception

- Psychiatric illness / social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance / pill diary

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LY2228820

Temozolomide

Radiation:
radiotherapy


Locations

Country Name City State
France CHU Amiens Sud-Salouel Amiens
France Institut Bergonié Bordeaux
France Centre François Baclesse Caen
France Centre Jean Perrin Clermont-Ferrand
France Centre Georges François Leclerc Dijon
France Centre Paul Strauss Strasbourg

Sponsors (3)

Lead Sponsor Collaborator
Centre Jean Perrin ARC Foundation for Cancer Research, National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary maximum tolerated dose (MTD) (phase I) of LY2228820 in combination with TMZ and radiotherapy during chemoradiotherapy period defined as the highest dose tested in which a dose limiting toxicity (DLT) is experienced by no more than 33% of patients during chemoradiotherapy period. from D1 Week 0 (first dose of LY2228820) to D63 Week 8.
Primary 6-month Progression Free Survival (PFS) rate (phase II) defined as the rate of patients who not presented a progression at 6 months from the first dose of LY2228820 6 months from the first dose of LY2228820
Secondary Safety profile according to NCI Common Toxicity Criteria for Adverse Effect (CTCAE) criteria version 4.03. from baseline to 30 days after treatment (concomitant and adjuvant treatment) (week 35)
Secondary PFS disease progression assessed per Response Assessment in Neuro-Oncology (RANO) criteria from the first dose of LY2228820 to disease progression or death for any reason, up to 24 months
Secondary Overall Survival from the first dose of LY2228820 to death, up to 24 months
Secondary 12-month PFS rate defined as the rate of patients who not presented a progression at 12 months from the first dose of LY2228820 12 months from the first dose of LY2228820
Secondary Objective response rate according to RANO criteria for patients with incomplete resection or only biopsy from the first dose of LY2228820 to treatment completion
Secondary The neurologic status evaluated by clinical assessment and Mini-Mental State Examination (MMSE) and evaluation of corticosteroid dosage from baseline to progression, up to 24 months
Secondary Pharmacokinetic of LY2228820 and TMZ (AUC0-12h) D7 Week 0, D28 Week 3, D35 Week 4
Secondary MAPKAPK-2 activation in tumor and stromal cells and Peripheral Blood Mononucleated Cells (PBMCs) baseline (tumor) D1 D7 week 0, D28 Week 3, D35 Week 4 (PBMCs)
Secondary Validated biomarker of glioblastoma (MGMT, IDH1 (isocitrate dehydrogenase 1), pTEN (phosphatase and tensin homolog), p53) on tumor baseline
See also
  Status Clinical Trial Phase
Terminated NCT02530502 - Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Phase 1
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00238303 - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Phase 2
Completed NCT02227901 - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT00049387 - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Phase 1
Completed NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02179086 - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Recruiting NCT04573140 - A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) Phase 1
Active, not recruiting NCT00823797 - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase 2
Completed NCT00045565 - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT01977677 - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Phase 1/Phase 2
Completed NCT01648348 - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00004262 - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Phase 1
Terminated NCT01575275 - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Phase 2
Terminated NCT01996527 - 3T MRI Biomarkers of Glioma Treatment Response Early Phase 1
Completed NCT01119599 - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Terminated NCT01103375 - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase 1
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00459381 - Pazopanib in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT00316849 - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1